Vstm

Hey there, fellow investors and financial adventurers! Sarah Miller here, and for over a decade, I’ve been deep in the trenches of market analysis, helping folks like you navigate the sometimes thrilling, often challenging world of investing. Today, I want to chat about a specific corner of the market that’s always a rollercoaster: biotech. Specifically, we’re going to talk about Verastem (VSIM) and what a recent downgrade tells us about commercialization, development, and how to think about such investments in your broader personal finance strategy. ...